gip glp 1 agonist tirzepatide GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 New Developments in Pharmacological Treatment

Design and evaluation of peptide dual-agonists of GLP-1 and NPY2 receptors for glucoregulation and weight loss with mitigated nausea and emesis

Long-acting dosage forms have more advantages in blood sugar control due to their longer half-life and stable blood concentration

Over the last couple of decades, Pratley says, the scientific research community has learned that incretin hormones, including GLP-1, GIP, and others, are important regulators of metabolism with impacts on glycemia, lipids, and body weight

In preclinical models, co-administration of bimagrumab or dual myostatin/activin A inhibitors with GLP-1R agonists preserves or increases muscle mass while enhancing fat loss, resulting in improved body composition and metabolic outcomes compared with GLP-1R agonist monotherapy [176]

GLP-1 Receptor Expression Within the Human Heart

PIO increased both body and visceral fat without affecting food consumption and also reduced urinary glucose excretion through suppression of glucosuria